Z
Zealand Pharma
Discovery, design and development of innovative peptide-based medicines
At a glance
- Founded
- 1998
- Headquarters
- Søborg, Denmark
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Zealand Pharma.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Series B and later4 investors entered at this stage
- VIVan Herk Investments
- SBSanofi-Genzyme BioVentures
- KPKurma Partners
- HIHBM Healthcare Investments
Ownership
Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (2026).
“Other / undisclosed” is the 72.5% not attributed to a named shareholder. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Alumni founders
Former Zealand Pharma employees who went on to found companies, sorted by Dealroom signal score.
PAPapaEst. 2017
Andrew ParkerUnited States
CTCarrick TherapeuticsEst. 2015
Elaine SullivanIreland
Christian GroendahlUnited Kingdom
Florian ReinaudFrance
Peter Holme JensenDenmarkGlobal footprint
team presence
across markets
Patents
117 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Zealand Pharma was the backer or acquirer, 2019–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Zealand Pharma's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Zealand Pharma deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Zealand Pharma's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zealand Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zealand Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.